Market Overview - The Hong Kong stock market experienced a rise followed by a slight retreat, with the Hang Seng Index closing at 27,183.15 points, up 0.58% or 155.99 points, and a total trading volume of HKD 234.04 billion [1] - The Hang Seng China Enterprises Index increased by 0.81% to 9,242.75 points, while the Hang Seng Tech Index rose by 0.62% to 5,451.03 points [1] Blue-Chip Stocks Performance - Pop Mart (09992) continued its upward trend, closing up 4.9% at HKD 269.8, contributing 14.96 points to the Hang Seng Index [2] - Other notable blue-chip stocks included: - CSPC Pharmaceutical Group (01093) up 5.52% at HKD 10.32, contributing 7.01 points [2] - Innovent Biologics (01801) up 4.98% at HKD 89.65, contributing 11.16 points [2] - New Oriental Education (09901) down 4.39% at HKD 46.66, detracting 2.61 points [2] - Alibaba Health (00241) down 2.07% at HKD 6.14, detracting 1.34 points [2] Sector Highlights - The biotechnology sector showed strong performance, with notable gains from: - CSPC Pharmaceutical Group (01093) up 5.52% [3] - Genscript Biotech (01672) up 5.15% [3] - Innovent Biologics (01801) up 4.98% [3] - WuXi Biologics (02269) up 4.65% [3] - The AI-related stocks also surged, with: - China Literature (00772) up 15.41% [4] - Zhiyun (02513) up 14.81% [4] - Fubo Group (03738) up 14.44% [4] Investment Opportunities - The global strategic cooperation between Innovent Biologics and Eli Lilly could reach a potential transaction value of USD 8.85 billion, indicating a strong start for 2026 in business development [4] - The North American electricity shortage is expected to drive investments in various technologies, with the Department of Energy predicting a peak shortfall of 20-40 GW by 2030 [6] Notable Stock Movements - Lexin Outdoor (02720) saw a significant increase of 102.29% on its first trading day, closing at HKD 24.78 [7] - Ruifeng New Energy (00527) rose by 12.9% after signing an investment framework agreement for a major AI computing center project in Zhangjiakou, with a total investment of approximately RMB 24 billion [8] - Jizhi Technology (02590) increased by 11.05% after launching a new general-purpose robot for warehouse scenarios [9] - Ninepoint Investment Holdings (09636) issued a profit warning, expecting revenue of approximately RMB 3.43 billion for 2025, a growth of about RMB 1.12 billion [10] - Changfei Optical Fiber (06869) reached a new high, closing up 8.88% as fiber prices have been rising due to supply-demand imbalances [11]

港股市场策略周报 港股市场策略周报 - 投资要点 l 港股市场表现回顾： n 除中小盘外，本周港股主要指数普遍下跌。本周恒生综指/恒生指数/恒生科技分别-3.22%/-3.02%/-6.51%。本周市 场一级行业板块中4个行业上涨、8个行业下跌，资讯科技业、原材料业、非必需性消费跌幅居前，分别下跌7.8%、 6.22%、4.55%。本周整体情况为：中小盘表现占优，其余风格的股指均有不同程度的下跌，其中恒生科技跌幅最深。 n 截至本周末，恒生综指的5年PE（TTM）估值分位点为88.51%，估值水平接近5年均值向上两个标准差。 l 港股市场宏观环境： 2 2026.02.02-2026.02.08 | 分析师： | 刘景锋 | | --- | --- | | 中央编号： | BXJ117 | | 联系电话： | 852-6222 4563 | | 邮箱： | liujingfeng@cnzsqh.hk | 1 n 基本面：2026年中央一号文件公布，强调确保国家粮食安全，发展农业新质生产力，实施"常态化精准帮扶"机制。 n 资金面：美联储3月维持利率不变的概率超8成；美国ISM PMI重返扩张区间；南向资金净流 ...

恒生港股通创新药指数是ETF跟踪的指数中首批"纯度"达100%的创新药指数，精准汇聚港股创新药领军 企业；中证港股通医药卫生综合指数从港股通范围内选取医药卫生行业中市值较大的50只上市公司作为 样本，覆盖创新药、医疗器械等领域。投资者可通过港股通创新药ETF易方达（159316）、港股通医药 ETF易方达（513200）等跟踪上述指数的产品，精准捕捉医药产业发展机遇。 1月30日，石药集团与阿斯利康达成总额高达185亿美元的合作，首付款12亿美元，创下中国药企对外授 权交易新纪录。2月8日，信达生物与礼来达成88.5亿美元合作，首付3.5亿美元，创新采用"端到端共 研"模式。据统计，2026年以来创新药BD合作的首付款规模，已超越2025年全年最高单季度水平，总交 易金额已达332.8亿美元，产业出海势头迅猛。 同时，龙头公司业绩预告验证了高景气度。信达生物、荣昌生物与君实生物预告2025年营业收入分别约 为110亿元、32.5亿元和25亿元，同比大幅增长45%、89%和32%，强劲的业绩增长为板块提供了坚实的 基本面支撑。 2月10日，港股医药板块全天强势领涨，截至15:15，恒生港股通创新药指数上涨2.7 ...

Core Viewpoint - Junshi Biosciences is actively developing a monkeypox recombinant protein vaccine in collaboration with several prestigious institutions, indicating a strong focus on innovative vaccine development and a commitment to expanding its product pipeline in the biopharmaceutical sector [2][3]. Company Developments - On October 27, 2023, Junshi Biosciences announced a partnership with Peking University, the Institute of Microbiology of the Chinese Academy of Sciences, Shanxi Higher Innovation Research Institute, and Beihang University to jointly develop a monkeypox recombinant protein vaccine [2]. - The company’s subsidiary, Junshi Biotech, is involved in the development of various vaccine-related products, including monkeypox and Zika vaccines, which are currently in the preclinical development stage [2]. Product Pipeline and Achievements - Junshi Biosciences has a comprehensive capability in the entire industry chain from drug discovery and development to large-scale production and commercialization, aiming to become a global innovative pharmaceutical company based in China [3]. - The company’s core product, Toripalimab, is the first domestically approved PD-1 monoclonal antibody in China, with 11 approved indications and one supplemental NDA under review. It has also received approvals in multiple countries including the U.S., EU, and Australia [3]. - The company is advancing its proprietary drug tifcemalimab, which is the first anti-BTLA monoclonal antibody to enter clinical development, with ongoing Phase III clinical trials and several Phase Ib/II studies in various tumor types [3]. Financial Performance - For the period from January to September 2025, Junshi Biosciences reported revenue of 1.806 billion yuan, representing a year-on-year growth of 42.06%. However, the net profit attributable to shareholders was a loss of 596 million yuan, although this reflects a 35.72% improvement compared to the previous year [9]. Technological Advancements - The company has deployed an AI translation platform that has replaced over 80% of external translation services for scientific literature, clinical trials, and quality management, enhancing operational efficiency [4]. Market Position - As of February 10, 2023, Junshi Biosciences had a market capitalization of 36.673 billion yuan, with a trading volume of 3.32 billion yuan and a turnover rate of 1.21% [1].

Group 1 - The Hong Kong stock market is experiencing a rally, with both the Hang Seng Index and the Hang Seng Tech Index rising over 1% [1] - The AI application and innovative pharmaceutical sectors are leading the gains in the market [1] - Companies such as Yu Wen Group and Zhi Pu have seen their stock prices increase by over 6%, while Kangfang Biotech and Innovent Biologics have risen by over 3% [1]

Group 1 - The core viewpoint of the article highlights the recovery of the innovative drug sector, with continuous capital inflow and a positive cycle driven by favorable policies, accelerated R&D, and international expansion [1] - The innovative drug ETF Guotai (517110) saw an intraday increase of over 2.4%, with a net capital inflow exceeding 200 million yuan in the past 20 days [1] - Multiple brokerages indicate that the domestic innovative drug industry is entering a favorable cycle characterized by normalized medical insurance negotiations, continuous clinical data releases, and successful License-out orders, enhanced by AI-driven R&D acceleration [1] Group 2 - The industry valuation is currently at a historical low to mid-range, with institutional allocation being relatively low, indicating ample room for future increases [1] - The innovative drug ETF Guotai (517110) tracks the CSI Hong Kong-Shenzhen-Shanghai Innovative Drug Industry Index (931409), which selects high-quality companies with strong R&D capabilities focused on biopharmaceuticals and chemical drug innovation [1] - The index includes leading innovative drug companies and high-growth targets, accurately reflecting the performance of the core medical innovation sector, with long-term growth potential and investment value [1]

Market Overview - The A-share market is experiencing narrow fluctuations, with a focus on AI applications, while traditional sectors like liquor and non-ferrous metals are facing declines, impacting major indices [1] - As of the midday break, the Shanghai Composite Index is at 4122.34 points, down 0.02%, the Shenzhen Component Index is down 0.02%, and the ChiNext Index is down 0.14%, while the Sci-Tech Innovation Board Index is up 0.19% [1] AI Application Sector - The AI application sector has seen significant activity, particularly in the "AI + Film" direction, leading to a surge in stock prices, with over ten film-related stocks hitting the daily limit [2] - Notable stocks include: - Jiecheng Co., Ltd. (300182) and Zhongwen Online (300364) both achieving a 20% increase for two consecutive days - Industry leader Light Media (300251) also rising by 20% [2][3] Seedance 2.0 Impact - The recent internal testing of ByteDance's Seedance 2.0 video model has sparked widespread discussion, showcasing its ability to create high-quality videos from text or images in just 60 seconds [4] - Analysts believe that Seedance 2.0 represents a breakthrough in AI capabilities, potentially revolutionizing the production of short content like AI dramas and significantly reducing costs and increasing efficiency in production [4] Innovative Drug Sector - The innovative drug sector is experiencing a revival after a period of stagnation, with Wanbangde (002082) hitting the daily limit and Guangshengtang (300436) rising over 8% [6] - The National Medical Products Administration has announced that by 2025, China's pharmaceutical industry will accelerate its internationalization, with innovative drug overseas licensing transactions expected to exceed $130 billion, marking a shift from a "generic drug production powerhouse" to an "innovative drug exporting powerhouse" [8]

Group 1: AI Application Sector - The AI application sector has seen a collective surge, with significant gains in cultural media, short drama games, and internet sectors, leading to multiple stocks hitting the daily limit up [1][2] - Notable stocks that reached the limit up include Reader Culture (20% increase), Chinese Online (20% increase), Light Media (20% increase), and others [2][3] - ByteDance's recent launch of Seedance 2.0, a video generation model, has been a key catalyst for this surge, showcasing impressive capabilities in video creation from various media inputs [3][4] Group 2: Innovative Drug Sector - The innovative drug sector experienced a rebound, with stocks like Haixiang Pharmaceutical and Wanbangde hitting the daily limit up, while several others rose over 5% [5][6] - The total transaction scale for China's innovative drug license-out is projected to reach a record $135.7 billion by 2025, indicating strong global value for domestic innovative drug pipelines [6][7] - Recent collaborations in January, including major deals like the one between Shiyao and AstraZeneca worth $18.5 billion, further validate the potential of Chinese innovative drugs [6][7]

Core Insights - The article emphasizes three key investment directions for 2026: the domestic AI ecosystem, innovative pharmaceuticals, and the commercial aerospace sector, which are expected to lead market trends [1][6]. Group 1: Domestic AI Ecosystem - The domestic AI ecosystem is anticipated to experience a comprehensive explosion this year, driven by rapid advancements in large model technology and increased application penetration [4][9]. - The AI industry in China is expected to replicate the growth trajectory seen overseas, positively impacting related sectors [9]. - The AI industry chain includes downstream areas focused on large models and cloud computing, while upstream sectors encompass AI chips, storage, semiconductor manufacturing, and related materials [9]. Group 2: Innovative Pharmaceuticals - The innovative pharmaceutical sector has shown signs of explosive growth over the past 2-3 years, despite experiencing a pullback due to valuation pressures in the latter half of last year [5][9]. - Companies with overseas capabilities and strong pipeline execution are seen as having favorable positioning for investment during current market adjustments [5]. Group 3: Commercial Aerospace Sector - The commercial aerospace sector, particularly in areas like rocket recovery and low-orbit satellites, is expected to accelerate commercialization over the next 5 to 10 years, presenting clear growth paths [5][9]. - This sector is characterized by both thematic and growth attributes, making it a focal point for investment [5].

Market Overview - The Hong Kong stock market indices collectively rose, with the Hang Seng Index increasing by 0.54% to 27,172.87 points, the Hang Seng Tech Index up by 0.84%, and the State-Owned Enterprises Index rising by 0.78% [1][9] Technology Sector - Tech stocks showed mixed performance, with Xiaomi, JD.com, and NetEase rising over 2%, while Meituan fell over 3% and Tencent dropped over 1% [1][9] - AI application stocks surged, particularly Zhiyun, which increased by over 21% following the internal testing of ByteDance's Seedance 2.0 video model [2][10] Pharmaceutical Sector - Innovative drug concept stocks collectively rose, with CSPC Pharmaceutical gaining over 6%. The company has entered a platform-level collaboration with AstraZeneca worth up to $18.5 billion [4][12] - The innovative drug sector is experiencing rapid revenue growth, with over 70% of companies expected to achieve positive revenue growth by 2025 [4][12] Consumer Sector - The new consumption concept saw some stocks rise, with Pop Mart increasing by over 4%. The company announced plans to sell over 400 million products globally by 2025 [5][13] New Listings - Two new stocks were listed today, with Lexin Outdoor surging over 121% and Aixin Yuan Zhi rising nearly 1% [6][14]